Results 71 to 80 of about 1,303,482 (284)
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer +7 more
wiley +1 more source
In 28 patients with intraventricular block and coronary heart disease (CHD), as well as in 20 professional ex-athletes with impaired intraventricular conductivity, corrected QT interval dispersion at maximal and minimal heart rate (HR) was assessed ...
Yu. N. Fedulaev +3 more
doaj
Introduction Reversal of non-depolarizing neuromuscular blocking agent neostigmine is associated with QT prolongation under general anesthesia. To clarify the effects of neostigmine and sugammadex on hemodynamic status, the QT interval and QT dispersion ...
Yusuke Yamashita +4 more
doaj +1 more source
QT is longer in drug-free patients with schizophrenia compared with age-matched healthy subjects. [PDF]
The potassium voltage-gated channel KCNH2 is a well-known gene in which mutations induce familial QT interval prolongation. KCNH2 is suggested to be a risk gene for schizophrenia.
Kumiko Fujii +9 more
doaj +1 more source
Effect of hemodialysis on corrected QT interval and QTc dispersion
Hemodialysis patients are at higher risk of cardiovascular disease due to traditional and dialysis-related risk factors. Our aim was to study the effects of hemodialysis on the corrected QT interval (QTc) and QTc dispersion in chronic kidney disease (CKD) without clinically manifest heart disease.
Sohal, P. M. +7 more
openaire +2 more sources
Variability of heart rate correction methods for the QT interval [PDF]
Aims To compare variability of heart rate‐corrected QT intervals (QTc) using three different methods in a study of low‐dose oral haloperidol.Methods In a randomized, double‐blind, placebo‐controlled, crossover trial, we studied QT interval pharmacodynamics of single doses of oral haloperidol (10 mg) in 16 healthy subjects.
Mehul, Desai +4 more
openaire +2 more sources
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source
Artificial intelligence in preclinical epilepsy research: Current state, potential, and challenges
Abstract Preclinical translational epilepsy research uses animal models to better understand the mechanisms underlying epilepsy and its comorbidities, as well as to analyze and develop potential treatments that may mitigate this neurological disorder and its associated conditions. Artificial intelligence (AI) has emerged as a transformative tool across
Jesús Servando Medel‐Matus +7 more
wiley +1 more source
Background The number of young patients with cardiac disease has recently increased. To describe the electrocardiogram characteristics and identify the possible factors affecting the characteristics in early life might be helpful for the prevention and ...
Shingo Nakashima +8 more
doaj +1 more source
Using a wearable electrocardiogram (ECG) patch adapted for 7‐day monitoring in the horse
Abstract Background Arrhythmias can cause poor performance and sudden death in horses. Long‐term (>24 h) electrocardiogram (ECG) monitoring has been used to identify arrhythmias in humans and is superior to short‐term monitoring for transient arrhythmia detection. Televet is the current equine gold‐standard ECG device. The Cardea SOLO™ (CS) is a single‐
Tatiana Delecave Dias +3 more
wiley +1 more source

